MindWalk Holdings Corp. (HYFT) – What Are Researchers Saying About This Stock?

MindWalk Holdings Corp. (NASDAQ:HYFT) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $5.00.

A number of research analysts have recently weighed in on HYFT shares. HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Weiss Ratings raised MindWalk from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 28th. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Zacks Research raised shares of MindWalk from a “strong sell” rating to a “hold” rating in a report on Monday, September 21st.

MindWalk Trading Up 6.0%

NASDAQ HYFT opened at $1.06 on Monday. The firm’s fifty day moving average price is $1.30 and its two-hundred day moving average price is $1.38. MindWalk has a fifty-two week low of $0.98 and a fifty-two week high of $2.99. The company has a quick ratio of 1.75, a current ratio of 1.84 and a debt-to-equity ratio of 0.43.

MindWalk (NASDAQ:HYFT) last announced its earnings results on Monday, September 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%. The business had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $3.25 million. As a group, sell-side analysts forecast that MindWalk will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MindWalk stock. BlackRock Inc. purchased a new position in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned about 0.33% of MindWalk as of its most recent filing with the Securities and Exchange Commission (SEC). 6.70% of the stock is currently owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.